Chiesi Group, an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals Inc. have entered into a definitive agreement under which Chiesi will acquire KalVista. Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for $27.00 per share in cash. The total value implied by the Transaction at closing is approximately $1.9 billion. The Transaction, which is expected to close in Q3 ...